Neuro-Oncology - McMaster Experts

publication venue for

HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402 2023
IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY 2023
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. 2023
DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS 2022
DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY 2022
ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA 2022
NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA. 2022
AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS 2021
ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER 2021
FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA 2021
THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS 2021
EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA 2021
EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION 2021
QOL-02. PERCEPTIONS OF LATE EFFECTS CARE NEEDS AMONG SURVIVORS OF PEDIATRIC BRAIN TUMOURS 2020
QOL-46. LATE EFFECTS CARE FOR CHILDHOOD BRAIN TUMOUR SURVIVORS: A QUALITY IMPROVEMENT PROJECT 2020
DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA 2020
PERCEPTIONS OF LATE EFFECTS CARE NEEDS AMONG SURVIVORS OF PEDIATRIC BRAIN TUMOURS 2020
EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS 2020
IDEAL TREATMENT REGIMEN FOR PATIENTS WITH >= 1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS 2020
IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS 2020
TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH 2020
FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402 2019
LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA 2019
MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE 2019
GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2019
MUSAShi-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA 2019
SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA 2019
A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS? 2018
DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS 2018
DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY 2018
MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA 2018
USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN GLIOMA PATIENTS 2018
INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA 2018
SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE 2018
A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS 2017
A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA 2017
CE7 CANADIAN CLINICAL TRIALS GROUP / ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY. A PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY (WBRT) FOR 5-15 BRAIN METASTASES 2017
CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS 2017
CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY 2017
CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS 2017
GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2017
GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY 2017
IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA 2017
N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS 2017
PATTERNS OF TTFIELDS-RELATED SEVERE SKIN TOXICITY IN GBM PATIENTS 2017
PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES 2017
PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES 2017
PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933 2017
THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA 2017
TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA 2017
CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS 2017
GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE 2017
INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI, IN GROUP 3 MEDULLOBLASTOMA 2017
ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA 2016
ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA 2016
CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES 2016
CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES 2016
DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS 2016
Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma 2016
THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA 2016
A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS 2016
ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS 2016
ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT? 2016
DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS? 2016
IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY? 2016
MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM 2016
NEURAL NETWORK DISTURBANCES IN CHILDREN TREATED FOR BRAIN TUMOURS 2016
REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY 2016
ACTIVATED Wnt SIGNALING TARGETS Sox2+TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS 2015
DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA 2015
NC-10 * TRAINING THE BRAIN TO REPAIR ITSELF: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS 2014
RM-06 * IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE 2014
SC-33 * POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT 2014
IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS 2014
GLIOMA SPECIFIC PEPTIDES: A PLATFORM FOR MOLECULAR IMAGING AND THERAPEUTIC TARGETING 2014
SOX2 IDENTIFIES THE TREATMENT-REFRACTORY STEM CELL POPULATION IN GROUP 2 MEDULLOBLASTOMA 2014
EPIDEMIOLOGY OF MALIGNANT PONTINE GLIOMAS (MPG) IN THE PAEDIATRIC POPULATION IN CANADA: A STUDY OF THE CANADIAN PAEDIATRIC BRAIN TUMOUR CONSORTIUM (CPBTC) 2014
EXERCISE INCREASES HIPPOCAMPAL VOLUME IN CHILDREN TREATED WITH CRANIAL RADIATION 2014
NEUROCOGNITIVE EVALUATION OF LONG TERM SURVIVOR'S WITH ATYPICAL TERATOID/RHABDOID TUMOR (ATRT): THE CANADIAN REGISTRY EXPERIENCE 2014
PERSONALIZING THE TREATMENT OF PEDIATRIC MEDULLOBLASTOMA: POLO-LIKE KINASE 1 AS A MOLECULAR TARGET IN HIGH-RISK CHILDREN 2014
PROGNOSTIC ADVANTAGE OF SURVEILLANCE NEUROIMAGING IN MANAGEMENT OF PEDIATRIC BRAIN TUMOURS 2014
DISTINGUISHING RESPONDERS FROM NON-RESPONDERS TO BEVACIZUMAB USING CT PERFUSION 2013
MEMORY PRESERVATION WITH CONFORMAL AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE- BRAIN RADIOTHERAPY (WBRT) FOR PATIENTS WITH BRAIN METASTASES: PRELIMINARY RESULTS OF RTOG 0933 2013
WEEKLY VINBLASTINE IN CHEMOTHERAPY NAIVE CHILDREN AND ADOLESCENT WITH UNRESECTABLE OR PROGRESSIVE LOW GRADE GLIOMA: A CANADIAN COOPERATIVE STUDY 2013
Bmi1 REGULATES GLI ACETYLATION THROUGH CULLIN3 IN MEDULLOBLASTOMA STEM CELLS 2013
CLONAL EVOLUTION OF MEDULLOBLASTOMA BRAIN TUMOUR-INITIATING CELLS (BTICS) IN RESPONSE TO THERAPY: DISCOVERING THE REFRACTORY BTIC POPULATION 2013
MYXOPAPILLARY SPINAL EPENDYMOMAS DISPLAY A HIF1-ALPHA DRIVEN 'WARBURG' PHENOTYPE 2013
PERSONALIZING THE TREATMENT FOR MEDULLOBLASTOMA: POLO-LIKE KINASE 1 (PLK1) AS A MOLECULAR TARGET FOR THE SONIC HEDGEHOG (SHH) SUBTYPE 2013
REGULATION OF MEDULLOBLASTOMA STEM CELL SELF-RENEWAL THROUGH THE DEVELOPMENTALLY CONSERVED FoxG1-Bmi1-p21 AXIS 2013
CHARACTERIZATION OF GLIOMA USING ULTRA-HIGH-FIELD MR SPECTROSCOPIC IMAGING 2012
PRIMARY MALIGNANT BRAIN TUMORS IN THE ELDERLY: RETROSPECTIVE ANALYSIS OF MANAGEMENT AND OUTCOME 2012
Bmi1 AND FoxG1 REGULATE SELF-RENEWAL IN CD15+non-Shh/Wnt SUBTYPE MEDULLOBLASTOMA STEM CELLS THROUGH RECIPROCAL PROMOTER OCCUPANCY 2012
Bmi1 REGULATION OF SONIC HEDGEHOG SIGNALING THROUGH THE E3 UBIQUITIN LIGASE CULLIN3 IN MEDULLOBLASTOMA STEM CELLS 2012
CHILDREN SURVIVING BRAIN TUMORS HAVE HIGH RATES OF OBESITY INDEPENDENT OF PUBERTY 2012
DEVELOPMENT OF IN VITRO AND IN VIVO CHEMO-AND RADIOTHERAPY MODELS FOR DETECTION OF TREATMENT-REFRACTORY MEDULLOBLASTOMA BRAIN TUMOR-INITIATING CELLS 2012
FITNESS, PHYSICAL ACTIVITY AND BODY COMPOSITION FOLLOWING TREATMENT FOR A CNS TUMOUR 2012
FRACTIONATED STEREOTACTIC RADIOSURGERY FOR RELAPSED PAEDIATRIC PRIMITIVE NEUROECTODERMAL TUMOURS: A SINGLE INSTITUTION EXPERIENCE 2012
HIGH-GRADE PAPILLARY TUMOUR OF THE PINEAL REGION IN A YOUNG CHILD WITH LEPTOMENINGEAL DISEASE 2012
INCIDENCE OF MEDULLOBLASTOMA IN CANADIAN CHILDREN 2012
PARENTAL KNOWLEDGE AND HEALTH CARE SATISFACTION WITH NEUROFIBROMATOSIS TYPE 1 2012
PEDIATRIC AND ADULT MEDULLOBLASTOMA: WHAT MAKES THE DIFFERENCE IN OUTCOME? 2012
PEDIATRIC INTRACRANIAL GERMINOMA CASE SERIES: FOUR PATIENTS WITH ATYPICAL CLINICO-RADIOLOGICAL PRESENTATION 2012
POLO-LIKE KINASE 1 (PLK1) INHIBITION KILLS GLIOBLASTOMA MULTIFORME BRAIN TUMOUR CELLS IN PART THROUGH LOSS OF SOX2 AND DELAYS TUMOUR PROGRESSION IN MICE 2012
RECURRENT ANAPLASTIC EPENDYMOMA WITH EXTRACRANIAL METASTASES - TREATMENT WITH SURGERY, RADIATION AND ORAL CHEMOTHERAPY 2012
STRATIFICATION ACCORDING TO HGG-IMMUNO RPA MODEL PREDICTS OUTCOME IN PATIENTS WITH RELAPSED MALIGNANT GLIOMA TREATED BY ADJUVANT POSTOPERATIVE DC VACCINATION 2012
YB-1 BRIDGES NEURAL STEM CELLS AND BRAIN TUMOR-INITIATING CELLS VIA ITS ROLES IN DIFFERENTIATION AND CELL GROWTH 2012
GENOME-WIDE METHYLATED DNA RECOVERY IDENTIFIES FREQUENT HYPERMETHYLATION OF NOVEL TUMOR SUPPRESSOR GENES IN THE EPENDYMOMA EPIMETHYLGENOME 2011
ROLE OF YB-1 ON GLIAL TUMORS AND ITS PROMISE AS A MOLECULAR TARGET 2011
TARGETING POLO-LIKE KINASE FOR THE TREATMENT OF BRAIN TUMORS AND ITS UNIQUE CAPACITY TO ELIMINATE CANCER STEM CELLS THROUGH Sox-2 INHIBITION 2011
Y-BOX BINDING PROTEIN-1 (YB-1) INHIBITION TRIGGERS DIFFERENTIATION OF NORMAL AND CANCER STEM CELLS FROM THE BRAIN 2011
EPENDYMOMAS OF THE FILUM TERMINALE: A SINGLE-INSTITUTION EXPERIENCE 2010
CLAUDIN-6 AND INI-1 IMMUNOHISTOCHEMICAL EXPRESSION IN ATYPICAL TERATOID RHABDOID TUMOURS OF THE CNS 2010
IMMUNOTHERAPY INTEGRATED IN RADIOCHEMOTHERAPY AND MAINTENANCE TENIOZOLOMIDE: FINAL RESULTS OF THE HGG-2006 STUDY 2010
LATE EPENDYMOMA RELAPSES: A CANADIAN PEDIATRIC MULTICENTRE STUDY 2010
MANAGEMENT OF AN INTRACRANIAL MATURE TERATOMA RECURRING AS A GERMINOMA 2010
MEDULLOBLASTOMA OVER THREE DECADES IN A SINGLE INSTITUTION - WHAT HAVE WE ACHIEVED 2010
REDEFINING THE INCIDENCE, OUTCOMES, AND PROGNOSTIC FACTORS FOR CNS ATYPICAL TERATOID RHABDOID TUMOURS AT BC CHILDREN'S HOSPITAL 2010
REGULATION OF BMI1 BY THE SHH PATHWAY IN HUMAN MEDULLOBLASTOMA BRAIN TUMOUR INITIATING CELLS 2010
INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GLIOBLASTOMA: FINAL RESULTS OF THE HGG-2006 PHASE I/II TRIAL 2009
PHASE II TRIAL OF CONVENTIONAL RADIOTHERAPY WITH STEREOTACTIC RADIOSURGERY TO HIGH-RISK TUMOR REGIONS AS DETERMINED BY MR SPECTROSCOPY IN PATIENTS WITH GLIOBLASTOMA MULTIFORME 2009
PILOMYXOID ASTROCYTOMA IN TWO DIFFERENT AGE GROUPS 2009
VALIDATION OF RPA CLASSIFICATION AS A PROGNOSTIC TOOL IN ADULT PATIENTS WITH RELAPSED HIGH-GRADE GLIOMA VACCINATED AT TIME OF RECURRENCE 2009
A RETROSPECTIVE REVIEW OF THE INCIDENCE OF BRAIN METASTASES IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER 2008
INTEGRATION OF DC VACCINATION IN THE PRIMARY TREATMENT OF ADULTS WITH GBM: UPDATE OF THE HGG-2006 PHASE I/II TRIAL 2008
CNS atypical teratoid rhabdoid tumor (ATRT) in children less than 36 months: A Canadian pediatric brain tumor consortium (CPBTC) experience 2008
Characterisation of the 4q12 amplicon in pediatric gliomas 2008
Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells: Developing novel animal models for glioma 2008
Phase 1 and pharmacokinetic studies of erlotinib administered concurrently with and after radiotherapy for children, adolescents, and young adults with high-grade glioma 2008
Spinal cord tumors in infancy: A Canadian pediatric brain tumor consortium report 2008
Cilengitide and synergy with radiation 2007
Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma 2007
Multiple recurrent genetic events converge on proper control of histone 3 lysine 9 methylation in pediatric medulloblastoma 2007
White matter integrity and core cognitive functions in children treated with cranial-spinal radiation: A diffusion tensor study 2007
Imaging findings related to adjuvant dendritic cell (DC) vaccination in patients with relapsed high-grade glioma 2006
Motexafin gadolinium (MGd) combined with whole-brain irradiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase 3 trials 2006
Prodige: A phase 3 randomized placebo-controlled trial of thromboprophylaxis using dalteparin low-molecular-weight heparin (LMWH) in patients with newly diagnosed malignant glioma 2005
High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model 2004
Intensive therapy for childhood atypical teratoid rhabdold tumor of the central nervous system: A single institution's experience with four cases and a review of the literature 2004
DDDR-42. LEVERAGING GENOME-WIDE CRISPR/CAS9 KNOCKOUT DRUG SCREENS TO IDENTIFY SENSITIZERS FOR PROTEOSOME INHIBITORS IN GLIOBLASTOMA. 26:viii135-viii135. 2024
EXTH-24. THERAPEUTIC TARGETING OF MISLOCALIZED NUCLEAR ENVELOPE PROTEINS INMYC-DRIVEN GROUP 3 MEDULLOBLASTOMA. 26:viii242-viii242. 2024
EXTH-51. ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS. 26:viii248-viii248. 2024
IMMU-65. TARGETING AXONAL GUIDANCE DEPENDENCIES IN GLIOBLASTOMA WITH ROBO1 CAR T CELLS. 26:viii167-viii167. 2024
STEM-17. THE UROKINASE RECEPTOR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN BRAIN CANCERS. 26:viii61-viii62. 2024
TMET-24. MULTI-OMIC CHARACTERIZATION OF THE TEMPORAL METABOLIC ADAPTATIONS UNDERPINNING THERAPY RESISTANCE AND TUMOR RECURRENCE IN GLIOBLASTOMA. 26:viii293-viii293. 2024
TMET-34. PYROPTOSIS IS AN ACQUIRED VULNERABILITY OF BRAIN METASTASES. 26:viii295-viii295. 2024
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.. 26:1670-1682. 2024
QOL-23. POTENTIAL MYELIN REPAIR AFTER IRRADIATED PEDIATRIC BRAIN TUMOR: A MAGNETIZATION TRANSFER IMAGING ANALYSIS. 26:0-0. 2024
EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. 25:v225-v225. 2023
QOL-18. HIGHER VINCRISTINE DOSES CORRELATE WITH LONGER OVERALL SURVIVAL: A POST-HOC ANALYSIS OF PARTICIPANTS RECEIVING PCV ON RTOG 9402. 25:v252-v252. 2023
P02.16.B COMPENSATORY CROSS-TALK BETWEEN AUTOPHAGY AND GLYCOLYSIS REGULATES SENESCENCE AND STEMNESS IN HETEROGENEOUS GLIOBLASTOMA TUMOR SUBPOPULATIONS. 25:ii33-ii33. 2023
P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY. 25:ii49-ii49. 2023
P10.22.B COMBINATION OF ARTS MIMETICS WITH AUTOPHAGY INHIBITORS AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME APOPTOSIS RESISTANCE IN GLIOBLASTOMA. 25:ii67-ii67. 2023
PL02.1.A DELINEATING AND TARGETING A NOVEL METABOLISM-BASED POST-TRANSLATIONAL MECHANISM REGULATING THE ABUNDANCE OF THE ‘UNDRUGGABLE’ ONCOPROTEIN C-MYC IN MEDULLOBLASTOMA. 25:ii1-ii2. 2023
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. 25:1123-1131. 2023
Corrigendum to: Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. 25:1010-1010. 2023
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. 25:137-145. 2023
DDDR-03. DEVELOPMENT OF NOVEL ANTI-BRAIN METASTASIS INHIBITORS. 24:vii98-vii99. 2022
EPCO-07. NON-GENOMIC DETERMINANTS OF TUMOR CELL PHENOTYPES IN ADULT GLIOBLASTOMA. 24:vii117-vii117. 2022
EXTH-81. ITGA5 IS A NOVEL IMMUNOTHERAPEUTIC TARGET AGAINST TREATMENT REFRACTORY MEDULLOBLASTOMA. 24:vii228-vii228. 2022
MODL-05. DISCOVERY OF DYNAMIC MINIMAL RESIDUAL DISEASE STATES IN ADULT GLIOBLASTOMA USING SINGLE CELL TECHNOLOGY. 24:vii291-vii292. 2022
Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant. 24:847-848. 2022
Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?. 24:226-228. 2022
EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER. 23:vi175-vi175. 2021
STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. 23:vi21-vi21. 2021
STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. 23:vi22-vi22. 2021
TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. 23:vi215-vi215. 2021
TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. 23:vi218-vi218. 2021
STEM-02. THERAPEUTIC INTERVENTION OF LUNG-, BREAST-, AND MELANOMA-BRAIN METASTASIS. 23:vi21-vi21. 2021
STEM-05. FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND UNRECOGNIZED PATHWAY DEPENDENCIES IN RECURRENT GLIOBLASTOMA. 23:vi22-vi22. 2021
TMOD-01. AN IN VIVO FUNCTIONAL GENOMICS SCREEN TO IDENTIFY NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS. 23:vi215-vi215. 2021
TMOD-15. CHARACTERIZATION OF THE MINIMAL RESIDUAL DISEASE STATE REVEALS DISTINCT EVOLUTIONARY TRAJECTORIES OF HUMAN GLIOBLASTOMA. 23:vi218-vi218. 2021
EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA. 23:i10-i10. 2021
EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO. 23:i49-i49. 2021
EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO. 23:i49-i49. 2021
EPCT-12. NATIONAL MULTICENTERED RETROSPECTIVE REVIEW OF DEMOGRAPHIC, TUMOUR AND INTRAOPERATIVE FEATURES ASSOCIATED WITH THE DEVELOPMENT OF CEREBELLAR MUTISM AFTER PEDIATRIC POSTERIOR FOSSA TUMOUR RESECTION. 23:i49-i49. 2021
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.. 23:894-904. 2021
MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. 22:iii399-iii399. 2020
MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA. 22:iii399-iii399. 2020
CTNI-01. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS. 22:ii40-ii41. 2020
CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539. 22:ii55-ii56. 2020
STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. 22:ii196-ii196. 2020
SURG-05. IDEAL TREATMENT REGIMEN FOR PATIENTS WITH ≥1 BRAIN METASTASIS FROM PRIMARY NON-SMALL-CELL LUNG CANCER – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. 22:ii204-ii204. 2020
TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. 22:ii213-ii213. 2020
CTNI-01. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS. 22:ii40-ii41. 2020
CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539. 22:ii55-ii56. 2020
STEM-01. TARGETING BRAIN METASTASIS-INITIATING CELLS: A PREVENTATIVE APPROACH. 22:ii196-ii196. 2020
TAMI-03. IDENTIFICATION OF NOVEL DRIVERS OF LUNG-TO-BRAIN METASTASIS THROUGH IN VIVO FUNCTIONAL GENOMICS. 22:ii213-ii213. 2020
ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402. 21:vi15-vi15. 2019
STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. 21:vi239-vi239. 2019
ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402. 21:vi15-vi15. 2019
STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA. 21:vi239-vi239. 2019
Updates in the management of intradural spinal cord tumors: a radiation oncology focus. 21:707-718. 2019
MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 21:ii108-ii108. 2019
MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. 21:ii112-ii113. 2019
THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. 21:ii117-ii117. 2019
MEDU-10. THERAPEUTIC TARGETING OF STEM CELL SELF-RENEWAL IN CHILDHOOD MEDULLOBLASTOMA: STRATEGIES FOR BLOCKING RECURRENCE. 21:ii105-ii105. 2019
MEDU-25. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICs CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 21:ii108-ii108. 2019
MEDU-44. MUSASHI-1 IS A MASTER REGULATOR OF ABERRANT TRANSLATION IN GROUP 3 MEDULLOBLASTOMA. 21:ii112-ii113. 2019
THER-14. SMALL MOLECULE INHIBITOR TARGETING SELF-RENEWAL AS A THERAPEUTIC OPTION FOR RECURRENT MEDULLOBLASTOMA. 21:ii117-ii117. 2019
GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. 20:vi107-vi107. 2018
PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. 20:vi208-vi208. 2018
RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. 20:vi234-vi235. 2018
TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. 20:vi273-vi273. 2018
GENE-21. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS?. 20:vi107-vi107. 2018
PDTM-21. MATCHING OF SINGLE CELL TRANSCRIPTOMICS FROM CEREBELLAR DEVELOPMENT IDENTIFIES PUTATIVE SUBGROUP SPECIFIC CELLS OF ORIGIN FOR MEDULLOBLASTOMA. 20:vi208-vi208. 2018
RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS. 20:vi234-vi235. 2018
TMOD-23. DYNAMIC PATTERNS OF GLIOBLASTOMA CLONAL EVOLUTION IN RESPONSE TO CHEMORADIOTHERAPY. 20:vi273-vi273. 2018
MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. 20:i119-i119. 2018
MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. 20:i133-i133. 2018
MBCL-09. SALVAGE THERAPY FOR CHILDHOOD MEDULLOBLASTOMA: A SINGLE CENTER EXPERIENCE. 20:i119-i119. 2018
MBRS-24. INVESTIGATING THE ROLE OF THE RNA BINDING PROTEIN, MUSASHI 1 IN PEDIATRIC GROUP 3 MEDULLOBLASTOMA. 20:i133-i133. 2018
CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. 19:vi46-vi46. 2017
CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. 19:vi49-vi49. 2017
CMET-48. CE7 CANADIAN CLINICAL TRIALS GROUP / ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY. A PHASE III TRIAL OF STEREOTACTIC RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY (WBRT) FOR 5–15 BRAIN METASTASES. 19:vi49-vi49. 2017
CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. 19:vi54-vi54. 2017
EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. 19:vi72-vi72. 2017
IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. 19:vi113-vi113. 2017
NCOG-02. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933. 19:vi137-vi138. 2017
NCOG-05. TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. 19:vi138-vi138. 2017
NCOG-06. N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS. 19:vi138-vi138. 2017
STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. 19:vi229-vi229. 2017
STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. 19:vi230-vi230. 2017
STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. 19:vi234-vi235. 2017
TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. 19:vi254-vi254. 2017
TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 19:vi255-vi255. 2017
TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. 19:vi255-vi255. 2017
CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES. 19:vi46-vi46. 2017
CMET-47. PRECLINICAL VALIDATION OF NOVEL THERAPEUTICS TARGETING A BMIC POPULATION IN HUMAN BRAIN METASTASES. 19:vi49-vi49. 2017
CSIG-22. A CD133-Akt-Wnt SIGNALING AXIS PROVIDES FUNCTIONAL INSIGHT INTO THE ROLE OF CD133 IN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. 19:vi54-vi54. 2017
EPID-17. A SINGLE CENTER RESTROSPECTIVE REVIEW OF RECURRENT OR TREATMENT REFRACTORY PEDIATRIC MEDULLOBLASTOMA. 19:vi72-vi72. 2017
IMMU-03. THERAPEUTIC TARGETING OF TUMORIGENIC EphA2+/EphA3+ BRAIN TUMOR INITIATING CELLS WITH BISPECIFIC ANTIBODY IN HUMAN GLIOBLASTOMA. 19:vi113-vi113. 2017
NCOG-02. PRETREATMENT VOLUME OF MRI-DETERMINED WHITE MATTER INJURY (WMI) PREDICTS COGNITIVE DECLINE AFTER HIPPOCAMPAL AVOIDANT (HA) WBRT FOR BRAIN METASTASES: SECONDARY ANALYSIS OF NRG ONCOLOGY RTOG 0933. 19:vi137-vi138. 2017
NCOG-06. N107C/CEC.3 (ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY/CANADIAN CANCER TRIALS GROUP): PHASE III TRIAL OF POST-OPERATIVE RADIOSURGERY COMPARED WITH WHOLE BRAIN RADIOTHERAPY FOR RESECTED METASTATIC BRAIN DISEASE: COGNITIVE FUNCTION OF LONG-TERM SURVIVORS. 19:vi138-vi138. 2017
STEM-17. CHARACTERIZATION OF THE CELL SURFACE PROTEOME IN RECURRENT GLIOBLASTOMA INITIATING CELLS. 19:vi229-vi229. 2017
STEM-21. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL Wnt PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. 19:vi230-vi230. 2017
STEM-42. GENOME-WIDE CRISPR SCREENS IN BRAIN TUMOR INITIATING CELLS (BTICS) IDENTIFY POTENT SENSITIZERS OF CONVENTIONAL CHEMORADIOTHERAPY. 19:vi234-vi235. 2017
TMOD-02. IDENTIFICATION OF NOVEL MARKERS OF TREATMENT-REFRACTORY RECURRENT GLIOBLASTOMA. 19:vi254-vi254. 2017
TMOD-03. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 19:vi255-vi255. 2017
TMOD-06. CLONAL DYNAMICS OF HUMAN GLIOBLASTOMA IN RESPONSE TO CHEMORADIOTHERAPY. 19:vi255-vi255. 2017
MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 19:iv44-iv44. 2017
TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. 19:iv54-iv54. 2017
TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. 19:iv58-iv58. 2017
MEDU-30. GENES PRESERVING STEM CELL STATE IN GROUP 3 MB BTICS CONTRIBUTE TO THERAPY EVASION AND RELAPSE. 19:iv44-iv44. 2017
TRTH-13. BMI1 IS A THERAPEUTIC TARGET IN RECURRENT MEDULLOBLASTOMA. 19:iv54-iv54. 2017
TRTH-29. CONTEXT-SPECIFIC TUMOR SUPPRESSIVE FUNCTION OF THE CANONICAL WNT PATHWAY IN PEDIATRIC MEDULLOBLASTOMA HIGHLIGHTS A THERAPEUTIC STRATEGY FOR TREATMENT-REFRACTORY SUBGROUPS. 19:iv58-iv58. 2017
OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial. 19:iii13-iii13. 2017
Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. 19:now177-now177. 2017
ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. 18:vi17-vi18. 2016
IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA. 18:vi98-vi98. 2016
TMOD-02. Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma. 18:vi207-vi207. 2016
TMOD-23. DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO- BRAIN METASTASIS TO IDENTIFY GENETIC REGULATORS OF BRAIN METASTASIS INITIATING CELLS. 18:vi211-vi212. 2016
TMOD-37. CHARACTERIZATION OF A UNIQUE BMIC POPULATION IN HUMAN BRAIN METASTASES. 18:vi214-vi215. 2016
AT-03ATYPICAL TERATOID RHABDOID TUMORS IN THE FIRST YEAR OF LIFE: SHOULD WE TREAT?. 18:iii1.2-iii1. 2016
CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. 18:iii16.2-iii16. 2016
EPI-04DOES DIAGNOSTIC DELAY AFFECT MORBIDITY IN CHILDREN DIAGNOSED WITH BRAIN TUMOURS?. 18:iii40.3-iii40. 2016
MB-22ACTIVATED Wnt SIGNALING FOR THE THERAPEUTIC TARGETING OF TREATMENT-REFRACTORY MEDULLOBLASTOMA STEM CELLS. 18:iii101.3-iii101. 2016
QOS-06REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY. 18:iii146.2-iii146. 2016
QOS-21A MODEL OF CARE FOR PEDIATRIC CNS TUMOR PATIENTS. 18:iii149.4-iii149. 2016
QOS-22IS A SEPARATE AFTERCARE CLINIC FOR PEDIATRIC CNS TUMOR PATIENTS NECESSARY?. 18:iii150.1-iii150. 2016
QOS-41NEURAL NETWORK DISTURBANCES IN CHILDREN TREATED FOR BRAIN TUMOURS. 18:iii154.2-iii154. 2016
CMS-02MRI AND SURGICAL PARAMETERS TO DETERMINE THE RISK OF A CEREBELLAR MUTISM. 18:iii16-iii16. 2016
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors. 18:350-360. 2016
ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). 17:v12-v13. 2015
ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. 17:v38.4-v39. 2015
ATPS-92Bmi1 IDENTIFIES TREATMENT-REFRACTORY STEM CELLS IN HUMAN GLIOBLASTOMA. 17:v38-v39. 2015
BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. 17:v51.5-v52. 2015
BMET-31DEVELOPMENT AND APPLICATION OF A NOVEL MODEL OF HUMAN LUNG-TO-BRAIN METASTASIS TO IDENTIFY UNIQUE METASTATIC GENE SIGNATURES. 17:v51-v52. 2015
NIMG-27USING MR PERFUSION TO STRATIFY PATIENTS WITH TREATED HIGH-GRADE GLIOMAS: DOES IT CORRELATE WITH OVERALL SURVIVAL?. 17:v159.3-v159. 2015
NIMG-27USING MR PERFUSION TO STRATIFY PATIENTS WITH TREATED HIGH-GRADE GLIOMAS: DOES IT CORRELATE WITH OVERALL SURVIVAL?. 17:v159-v159. 2015
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. 17:1504-1513. 2015
STEM-23PYRVINIUM TARGETS CD133 IN HUMAN GLIOBLASTOMA BRAIN TUMOR-INITIATING CELLS. 17:v213.1-v213. 2015
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. 17:868-881. 2015
MB-14 * DISCOVERING THE TREATMENT REFRACTORY BTIC POPULATION IN GROUP 3 MEDULLOBLASTOMA. 17:iii22-iii22. 2015
MB-15 * ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. 17:iii23-iii23. 2015
MB-15ACTIVATED Wnt SIGNALING TARGETS Sox2+ TREATMENT-REFRACTORY Shh-DEPENDENT MEDULLOBLASTOMA STEM CELLS. 17:iii23-iii23. 2015
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. 17:430-439. 2015
RM-06IN VITRO CLONAL EVOLUTION OF GLIOBLASTOMA (GBM) BRAIN TUMOUR INITIATING CELLS (BTIC) TO MODEL TUMOUR RECURRENCE. 16:v187-v187. 2014
SC-33POLYCOMB GROUP PROTEIN Bmi1 CONTROLS NEURAL STEM AND PROGENITOR CELL MAINTENANCE AND GLIOBLASTOMA TUMOUR DEVELOPMENT. 16:v204-v204. 2014
P17.73 * IN VITRO ANALYSIS OF CYTOTOXIC EFFECTS OF BRIVARACETAM AND LACOSAMIDE ON HUMAN GLIOBLASTOMA CELLS. 16:ii104-ii104. 2014
MEDULLOBLASTOMA. 16:i71-i96. 2014
Abstracts from the 2011 BNOS Conference, June 29 – July 1, 2011, Homerton College, Cambridge. 13:ii1-ii14. 2011
Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: Correlation with IQ. 8:244-252. 2006

Neuro-Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)